Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union
29/06/2026 02:31
BRIEF-Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union June 29 (Reuters) - Neuren Pharmaceuticals Ltd NEU.AX:
DAYBU RECOMMENDED FOR APPROVAL IN EUROPEAN UNION
IF MARKETING AUTHORISATION GRANTED AND LAUNCHED, CO ENTITLED US$35 MILLION FOLLOWING FIRST COMMERCIAL SALE IN EU
Further company coverage: NEU.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuren Pharmaceuticals
See all newsStrong partner sales propel Neuren Pharmaceuticals to top of Australia benchmark
Brief: Neuren Pharmaceuticals Says DAYBU Recommended For Approval In European Union
Australia's Neuren jumps as EU committee backs key drug authorisation
Brief: Neuren Pharmaceuticals Reassessing Capital Management Options
Brief: Neuren Pharmaceuticals Says Daybue Stix Now Broadly Available In US For Rett Syndrome